The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 (“Stabilizing alkylglycoside compositions and methods thereof”) to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is used to treat acromegaly and carcinoid syndrome.
In July 2014, Aegis Therapeutics announced that it was looking to license its intranasal octreotide.
According to Aegis, the company now has over 75 issued patents and patents pending covering formulations that use its Intravail transmucosal enhancement technology and ProTek protein stabilitzation technology which can be used for a variety of non-invasive delivery methods including intranasal, buccal, and inhalation.
Read the Aegis Therapeutics press release.
